REFERENCE
Kirbach S, Simpson K, Nietert P, Mintzer J.A Markov model of the cost-effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease. Clinical Drug Investigation 28: 291-303, No. 5, 2008
Rights and permissions
About this article
Cite this article
Olanzapine worth it for agitation, psychosis in AD. Pharmacoecon. Outcomes News 553, 9 (2008). https://doi.org/10.2165/00151234-200805530-00014
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805530-00014